Showing results (651-660 of 706) with videos related to

Sort By:
Pageof 71
Clinical and Translational Science|January 26, 2017
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and LaunchH Scheerens, A Malong, K Bassett, et al.
The Lancet. Gastroenterology & Hepatology|October 10, 2024
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 studyMan-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, et al.
American Journal of Hematology|May 26, 2016
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLLIan W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, et al.
Oral Oncology|July 27, 2019
Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trialK Misiukiewicz, V Gupta, B A Miles, et al.
The AAPS Journal|April 19, 2011
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometryU V R Vijaya Saradhi, Sneha V Gupta, Ming Chiu, et al.
BJU International|January 28, 2020
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertionsRussell W Madison, Sumati V Gupta, Yasir Y Elamin, et al.
Transboundary and Emerging Diseases|February 7, 2019
Phylogenetic analysis of haemagglutinin gene deciphering a new genetically distinct lineage of canine distemper virus circulating among domestic dogs in IndiaM Bhatt, K K Rajak, S Chakravarti, et al.
AJNR. American Journal of Neuroradiology|June 7, 2022
Brain Abnormalities and Epilepsy in Patients with Parry-Romberg SyndromeC De la Garza-Ramos, A Jain, S A Montazeri, et al.
Leukemia Research|August 10, 2010
What are RBC-transfusion-dependence and -independence?R P Gale, G Barosi, T Barbui, et al.
Leukemia & Lymphoma|November 11, 2016
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLLTadeusz Robak, Krzysztof Warzocha, K Govind Babu, et al.
Pageof 71